Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 5;9(1):47.
doi: 10.3390/healthcare9010047.

Incidence and Clinical Impacts of COVID-19 Infection in Patients with Hemodialysis: Systematic Review and Meta-Analysis of 396,062 Hemodialysis Patients

Chun-Yu Chen  1   2 , Shih-Chieh Shao  3   4 , Yih-Ting Chen  1   2 , Cheng-Kai Hsu  1   2 , Heng-Jung Hsu  1   2 , Chin-Chan Lee  1   2 , Chiao-Yin Sun  1   2 , Yung-Chan Chen  2   5 , Ming-Jui Hung  6 , I-Wen Wu  1   2
Affiliations

Incidence and Clinical Impacts of COVID-19 Infection in Patients with Hemodialysis: Systematic Review and Meta-Analysis of 396,062 Hemodialysis Patients

Chun-Yu Chen et al. Healthcare (Basel). .

Abstract

Hemodialysis (HD) patients are highly susceptible to COVID-19 infection. However, comprehensive assessments of current evidence regarding COVID-19 in HD patients remain incomplete. We systematically searched PUBMED and EMBASE for articles published on incidence or mortality of COVID-19 infection in HD patients until September 2020. Two independent researchers extracted data and study-level risk of bias across studies. We conducted meta-analysis of proportions for incidence and mortality rate. Study heterogeneity and publication bias were assessed. A total of 29 articles with 3261 confirmed COVID-19 cases from a pool of 396,062 HD patients were identified. Incidence of COVID-19 in these HD patients was 7.7% (95% CI: 5.0-10.9%; study heterogeneity: I2 = 99.7%, p < 0.001; risk of publication bias, Egger's test, p < 0.001). Overall mortality rate was 22.4% (95% CI: 17.9-27.1%; study heterogeneity: I2 = 87.1%, p < 0.001; risk of publication bias, Egger's test: p = 0.197) in HD patients with COVID-19. Reported estimates were higher in non-Asian than Asian countries. Quality of study may affect the reported incidence but not the mortality among studies. Both incidence and mortality of COVID-19 infection were higher in HD patients. Available data may underestimate the real incidence of infection. International collaboration and standardized reporting of epidemiological data should be needed for further studies.

Keywords: COVID-19; hemodialysis; incidence; meta-analysis; mortality; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of literature search and selection.
Figure 2
Figure 2
Incidence rate of COVID-19 infection in patients with hemodialysis. The study of Li J et al [13]. reported two independent cohorts that were analyzed separately for meta-analysis. HD, hemodialysis; CI, confidential interval.
Figure 3
Figure 3
Treatment regimen used and proportion of high mortality (>30%) in different studies. Three main patterns were identified among 11 studies. Chi-square test, p = 0.587.
Figure 4
Figure 4
Mortality rate in hemodialysis patients with COVID-19 infection. The study of Li J et al [13]. reported two independent cohorts that were analyzed separately for meta-analysis. The second cohort of Li J et al. reported mortality in 57 deaths from 639 COVID-19 cases (all cases showed feature of viral pneumonitis and 109 were further confirmed by nuclear acid testing). HD, hemodialysis; CI, confidential interval. HD, hemodialysis; CI, confidential interval.
Figure 5
Figure 5
Impact of use of isolation strategies on the outcome of COVID-19 infection in HD patients. The impacts of applying isolation strategies at HD facilities on the (a) incidence (p = 1.0) and (b) mortality (p = 0.088) of COVID-19 was not significant. p value between groups by using Fisher’s exact test.
See this image and copyright information in PMC

References

    1. WHO Coronavirus Disease (COVID-19) Dashboard. [(accessed on 30 November 2020)];2020 Available online: https://covid19.who.int.
    1. McMichael T.M., Currie D.W., Clark S., Pogosjans S., Kay M., Schwartz N.G., Lewis J., Baer A., Kawakami V., Lukoff M.D., et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. N. Engl. J. Med. 2020;382:2005–2011. doi: 10.1056/NEJMoa2005412. - DOI - PMC - PubMed
    1. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed
    1. Rao K.S., Suryaprakash V., Senthilkumar R., Preethy S., Katoh S., Ikewaki N., Abraham S.J.K. Role of immune dysregulation in increased mortality among a specific subset of COVID-19 patients and immune-enhancement strategies for combatting through nutritional supplements. Front. Immunol. 2020;11:1548. doi: 10.3389/fimmu.2020.01548. - DOI - PMC - PubMed
    1. GBD Chronic Kidney Disease Collaboration Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–733. doi: 10.1016/S0140-6736(20)30045-3. - DOI - PMC - PubMed

LinkOut - more resources